116
Participants
Start Date
May 31, 2010
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
imetelstat
9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
Bevacizumab
Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
Auerbach Hematology Oncology, Baltimore
Krankenhaus Grosshansdorf, Grosshansdorf
Blumenthal Cancer Center, Charlotte
South Carolina Oncology Associates, Columbia
Integrated Community Oncology Network, Jacksonville
H. Moffitt Lee Cancer Center, Tampa
Florida Cancer Specialists, Fort Myers
Achieve Clinical Research, Llc, Birmingham
Clearview Cancer Institute, Huntsville
Sarah Cannon Research Institute, Nashville
The Jones Clinic, Germantown
Montgomery Cancer Center, Mount Sterling
Karmanos Cancer Institute, Detroit
University of Wisconsin, Madison
Universitaetsklinikum Mainz, Mainz
Hematology Oncology Centers, Billings
Ingalls Memorial Hospital, Harvey
Krankenhaus Nordwest, Frankfurt
Cancer Center of Kansas, Wichita
UT Southwestern Medical Center, Dallas
Scott and White Memorial Hospital (Texas A & M), Temple
University of Colorado Denver School of Medicine, Aurora
Asklepios Klinik Gauting GmbH, Gauting
Pacific Cancer Medical Center, Inc., Anaheim
St. Joseph's Hospital, Orange
Cancer Care Associates of Fresno Medical Group Inc, Fresno
Kaiser Permanente Medical Center, Vallejo
Kaiser Northwest, Portland
Swedish Cancer Institute, Seattle
Northwest Medical Specialties, Tacoma
Hôpital Charles Lemoyne, Greenfield Park
Hospital Notre-Dame, Montreal
Klinikum rechts der Isar der TU München, München
Lead Sponsor
Geron Corporation
INDUSTRY